JP7746272B2 - 慢性閉塞性肺疾患を管理するための組成物 - Google Patents

慢性閉塞性肺疾患を管理するための組成物

Info

Publication number
JP7746272B2
JP7746272B2 JP2022543653A JP2022543653A JP7746272B2 JP 7746272 B2 JP7746272 B2 JP 7746272B2 JP 2022543653 A JP2022543653 A JP 2022543653A JP 2022543653 A JP2022543653 A JP 2022543653A JP 7746272 B2 JP7746272 B2 JP 7746272B2
Authority
JP
Japan
Prior art keywords
composition
increased
chronic obstructive
obstructive pulmonary
pulmonary disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022543653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512489A5 (enExample
JP2023512489A (ja
Inventor
ムハンメド マジード
カリアナム ナガブシャナム
サラング バニ
アンジャリ パンデイ
Original Assignee
サミ－サビンサ グループ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サミ－サビンサ グループ リミテッド filed Critical サミ－サビンサ グループ リミテッド
Publication of JP2023512489A publication Critical patent/JP2023512489A/ja
Publication of JP2023512489A5 publication Critical patent/JP2023512489A5/ja
Application granted granted Critical
Publication of JP7746272B2 publication Critical patent/JP7746272B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022543653A 2020-01-17 2021-01-16 慢性閉塞性肺疾患を管理するための組成物 Active JP7746272B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062962343P 2020-01-17 2020-01-17
US62/962,343 2020-01-17
US202063126920P 2020-12-17 2020-12-17
US63/126,920 2020-12-17
PCT/US2021/013763 WO2021146648A1 (en) 2020-01-17 2021-01-16 Compositions for managing chronic obstructive pulmonary disease

Publications (3)

Publication Number Publication Date
JP2023512489A JP2023512489A (ja) 2023-03-27
JP2023512489A5 JP2023512489A5 (enExample) 2024-01-24
JP7746272B2 true JP7746272B2 (ja) 2025-09-30

Family

ID=76856592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022543653A Active JP7746272B2 (ja) 2020-01-17 2021-01-16 慢性閉塞性肺疾患を管理するための組成物

Country Status (9)

Country Link
US (1) US11925606B2 (enExample)
EP (1) EP4090340B1 (enExample)
JP (1) JP7746272B2 (enExample)
KR (1) KR20220128382A (enExample)
CN (1) CN115175672B (enExample)
AU (1) AU2021207536B2 (enExample)
BR (1) BR112022014114A2 (enExample)
CA (1) CA3164013A1 (enExample)
WO (1) WO2021146648A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023554642A (ja) * 2020-12-17 2023-12-28 サミ－サビンサ グループ リミテッド ビスデメトキシクルクミン組成物の抗肥満能
WO2022203721A1 (en) * 2021-03-25 2022-09-29 Muhammed Majeed Compositions and methods for inhibiting proteolytic activation of viruses
RS20220433A1 (sr) 2022-05-11 2023-11-30 Milan Prokin Višeciljni antivirusni dodatak ishrani

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016204264A (ja) 2015-04-15 2016-12-08 株式会社セラバリューズ 酸化変性ｌｄｌ複合体抑制剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20100179103A1 (en) * 2008-07-21 2010-07-15 Ketan Desai Curcumin cyclodextrin combination for preventing or treating various diseases
US8486909B2 (en) * 2009-06-24 2013-07-16 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
EP2475380A1 (en) * 2009-09-11 2012-07-18 Protaffin Biotechnologie AG Composition for treatment of cxcl8-mediated lung inflammation
WO2012047674A2 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
ITMI20132169A1 (it) * 2013-12-20 2015-06-21 Thompson S R L Composizione per la prevenzione ed il trattamento della bpco e della sintomatologia correlata
JP2017516764A (ja) * 2014-04-18 2017-06-22 オムニアクティブ ヘルス テクノロジーズ リミテッド クルクミン組成物及びその使用
WO2016145159A1 (en) * 2015-03-10 2016-09-15 The Research Foundation For The State University Of New York Chemically modified curcumins for use in the production of lipoxins
CN105998043B (zh) * 2016-07-01 2018-11-27 吉林大学 槐属双苷在制备防治慢性阻塞性肺疾病药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016204264A (ja) 2015-04-15 2016-12-08 株式会社セラバリューズ 酸化変性ｌｄｌ複合体抑制剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Diana Lelli et al.，Pharmacological Research，2017年，Vol.115，p.133-148
Feng Tang and Chunhua Ling，Journal of International Medical Research ，2019年，Vol.47, No.10，4764-4774
Masaru Suzuki et al.，Lung Cellular and Molecular Physiology，2009年，Vol.296, No.4，L614-623

Also Published As

Publication number Publication date
US11925606B2 (en) 2024-03-12
CN115175672A (zh) 2022-10-11
AU2021207536B2 (en) 2025-04-10
CA3164013A1 (en) 2021-07-22
NZ790708A (en) 2025-05-02
CN115175672B (zh) 2024-07-02
WO2021146648A1 (en) 2021-07-22
BR112022014114A2 (pt) 2022-09-13
JP2023512489A (ja) 2023-03-27
AU2021207536A1 (en) 2022-08-11
KR20220128382A (ko) 2022-09-20
US20210220290A1 (en) 2021-07-22
EP4090340A1 (en) 2022-11-23
EP4090340B1 (en) 2026-05-06
EP4090340A4 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
Xiong et al. PM2. 5-induced lung injury is attenuated in macrophage-specific NLRP3 deficient mice
AU2021207536B2 (en) Compositions for managing chronic obstructive pulmonary disease
Boulet et al. Bronchial subepithelial fibrosis correlates with airway responsiveness to methacholine
McMillan et al. Prolonged allergen challenge in mice leads to persistent airway remodelling
Pawliczak et al. Pathogenesis of nasal polyps: an update
Hepokoski et al. Altered lung metabolism and mitochondrial DAMPs in lung injury due to acute kidney injury
Choudhury et al. Role of inflammation and oxidative stress in the pathology of ageing in COPD: potential therapeutic interventions
Liu et al. Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects
Yang et al. Tanshinone IIA: a Chinese herbal ingredient for the treatment of atherosclerosis
Ye et al. Aloperine suppresses LPS-induced macrophage activation through inhibiting the TLR4/NF-κB pathway
Boulet et al. Airway inflammation and structural changes in airway hyper‐responsiveness and asthma: an overview
Kang et al. Dai-Huang-Fu-Zi-Tang alleviates pulmonary and intestinal injury with severe acute pancreatitis via regulating aquaporins in rats
Shi et al. Mitochondrial dysfunction: an emerging link in the pathophysiology of cardiorenal syndrome
Yan et al. The application of proteomics and metabolomics to reveal the molecular mechanism of Nutmeg-5 in ameliorating cardiac fibrosis following myocardial infarction
Abu-Elsaad et al. The falconoid luteolin mitigates the myocardial inflammatory response induced by high-carbohydrate/high-fat diet in wistar rats
Lyu et al. Anti‐inflammatory effects of reticuline on the JAK2/STAT3/SOCS3 and p38 MAPK/NF‐κB signaling pathway in a mouse model of obesity‐associated asthma
Sumi et al. Structural changes and airway remodelling in occupational asthma at a mean interval of 14 years after cessation of exposure
Lee et al. Distribution of RANTES and interleukin-5 in allergic nasal mucosa and nasal polyps
Lee et al. Anti-asthmatic effects of phenylpropanoid glycosides from Clerodendron trichotomum leaves and Rumex gmelini herbes in conscious guinea-pigs challenged with aerosolized ovalbumin
AU2019240210B2 (en) Liver protectant compositions and therapeutic applications
Li et al. Decreased plasma apolipoprotein AIV levels in patients with acute coronary syndrome
Sharma et al. The distribution and density of airway vasoactive intestinal polypeptide (VIP) binding sites in cystic fibrosis and asthma
Das et al. Age-dependent differential expression of apoptosis markers in the gingival tissue
Arora et al. Effect of Toll-like Receptor-3 Antagonist on Viral Asthma Exacerbations Via a TLR3/dsRNA Complex Pathway
Liu et al. GTS-21 Alleviates Acute Lung Injury by Enhancing GLP-1 Secretion and Regulating Alveolar Surfactant Proteins via α7nAChR Activation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240116

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250818

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250917

R150 Certificate of patent or registration of utility model

Ref document number: 7746272

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150